18.02.2016
Four extensive multicenter randomized trials have been completed which evaluated the safety and efficacy of two release-active drugs – liquid Ergoferon and Rengalin – in children and adults with acute respiratory infections (ARIs).
Ergoferon is a new antiviral compound with anti-inflammatory and antihistamine effects which is indicated for use in combination treatment of viral ARIs, including the flu, and is essentially composed of release-active anti-IFN-gamma, anti-histamine and anti-CD4 antibodies. Two placebo-controlled efficacy and safety studies of liquid Ergoferon involved 648 participants with viral ARIs recruited by 30 clinical centers.
